INTERVIEW: Glivec and the Indian healthcare conundrum
This article was originally published in Scrip
It is not the easiest of times to be heading Novartis India. The Supreme Court decision to decline a patent for Glivec (imatinib mesylate), which sparked a global debate on the alleged profiteering practices of big pharma, shows that the challenges are many for those in leadership positions in out-of-pocket markets like India.
You may also be interested in...
Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.
The coronavirus pandemic has thrown up unprecedented challenges for the Indian clinical trials segment, as in other parts of the world. Experts tell Scrip how things are poised in the country including potential impact on some critical milestones, but efforts are underway to tackle the crisis.